|
US6046166A
(en)
*
|
1997-09-29 |
2000-04-04 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6037323A
(en)
*
|
1997-09-29 |
2000-03-14 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6004925A
(en)
*
|
1997-09-29 |
1999-12-21 |
J. L. Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6287590B1
(en)
|
1997-10-02 |
2001-09-11 |
Esperion Therapeutics, Inc. |
Peptide/lipid complex formation by co-lyophilization
|
|
MXPA01009893A
(es)
|
1999-04-01 |
2003-07-28 |
Esperion Therapeutics Inc |
Compuestos con eter, composiciones y usos de estos.
|
|
UA81216C2
(en)
*
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
|
US7407663B2
(en)
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified immunodeficiency virus particles
|
|
US7439052B2
(en)
|
2000-06-29 |
2008-10-21 |
Lipid Sciences |
Method of making modified immunodeficiency virus particles
|
|
US20090017069A1
(en)
|
2000-06-29 |
2009-01-15 |
Lipid Sciences, Inc. |
SARS Vaccine Compositions and Methods of Making and Using Them
|
|
US7407662B2
(en)
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified viral particles with immunogenic properties and reduced lipid content
|
|
US7199102B2
(en)
*
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
US7144862B2
(en)
*
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
US7148197B2
(en)
*
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
|
US7166578B2
(en)
|
2000-08-24 |
2007-01-23 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
US7723303B2
(en)
|
2000-08-24 |
2010-05-25 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
|
US6664230B1
(en)
*
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
DK1335938T3
(da)
*
|
2000-11-10 |
2010-12-13 |
Hoffmann La Roche |
Apolipoprotein-konstruktion
|
|
AU2002213843B2
(en)
|
2000-11-10 |
2008-02-07 |
F. Hoffmann-La Roche Ltd. |
Apolipoprotein analogues
|
|
US6991727B2
(en)
*
|
2001-06-25 |
2006-01-31 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
|
AU2002322284A1
(en)
|
2001-06-25 |
2003-01-08 |
Lipid Sciences, Inc. |
Systems and methods using multiple solvents for the removal of lipids from fluids
|
|
US20060060520A1
(en)
|
2001-06-25 |
2006-03-23 |
Bomberger David C |
Systems and methods using a solvent for the removal of lipids from fluids
|
|
US20050260256A1
(en)
*
|
2001-09-28 |
2005-11-24 |
Hill Knut R |
Methods and apparatus for extrusion of vesicles at high pressure
|
|
CA2460787A1
(en)
*
|
2001-09-28 |
2003-04-03 |
Esperion Therapeutics, Inc. |
Prevention and treatment of restenosis by local administration of drug
|
|
AU2002360489A1
(en)
*
|
2001-12-07 |
2003-06-23 |
The Regents Of The University Of California |
Treatment for age-related macular degeneration
|
|
US7470659B2
(en)
*
|
2001-12-07 |
2008-12-30 |
The Regents Of The University Of California |
Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
|
|
US20030229062A1
(en)
*
|
2001-12-07 |
2003-12-11 |
The Regents Of The University Of California |
Treatments for age-related macular degeneration (AMD)
|
|
US6930085B2
(en)
*
|
2002-04-05 |
2005-08-16 |
The Regents Of The University Of California |
G-type peptides to ameliorate atherosclerosis
|
|
US20040009216A1
(en)
*
|
2002-04-05 |
2004-01-15 |
Rodrigueza Wendi V. |
Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
|
|
US20100204103A1
(en)
*
|
2002-05-08 |
2010-08-12 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
|
US7691965B2
(en)
*
|
2002-05-08 |
2010-04-06 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
|
BR0310100A
(pt)
*
|
2002-05-17 |
2007-04-27 |
Esperion Therapeutics Inc |
métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
|
|
JP2006507223A
(ja)
*
|
2002-05-17 |
2006-03-02 |
エスペリオン セラピューティクス，インコーポレイテッド |
脂質代謝異常疾患の治療方法
|
|
NL1020962C2
(nl)
*
|
2002-06-28 |
2003-12-30 |
Tno |
Therapie en prognose/monitoring bij sepsis en septische shock.
|
|
AU2003248786A1
(en)
*
|
2002-07-03 |
2004-01-23 |
Esperion Therapeutics, Inc. |
Compositions comprising panthetine for the treatment of dyslipidemia
|
|
US9655865B2
(en)
|
2002-07-29 |
2017-05-23 |
Veroscience, Llc |
Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
|
|
US20040220190A1
(en)
*
|
2002-07-29 |
2004-11-04 |
Cincotta Anthony H. |
Methods of treating metabolic syndrome using dopamine receptor agonists
|
|
US20080200453A1
(en)
|
2002-07-29 |
2008-08-21 |
Cincotta Anthony H |
Methods of treating metabolic syndrome using dopamine receptor agonists
|
|
US8821915B2
(en)
|
2002-08-09 |
2014-09-02 |
Veroscience, Llc |
Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
|
|
US20040081678A1
(en)
*
|
2002-08-09 |
2004-04-29 |
Anthony Cincotta |
Therapeutic process for the treatment of obesity and associated metabolic disorders
|
|
MXPA05004290A
(es)
*
|
2002-10-24 |
2005-11-23 |
Enos Pharmaceuticals Inc |
Formulaciones de l-arginina de liberacion sostenida, y metodos para su fabricacion y uso.
|
|
PT2404890T
(pt)
*
|
2003-01-23 |
2017-10-23 |
Esperion Therapeutics Inc |
Compostos de hidroxilo e composições para gestão do colesterol e utilizações relacionadas
|
|
JP2007527387A
(ja)
|
2003-07-03 |
2007-09-27 |
リピッド サイエンシーズ，インコーポレイテッド |
脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置
|
|
US7393826B2
(en)
|
2003-07-03 |
2008-07-01 |
Lipid Sciences, Inc. |
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
|
|
EP1699527A1
(de)
|
2004-01-02 |
2006-09-13 |
Advanced Cardiovascular Systems, Inc. |
Mit lipoprotein hoher dichte beschichtete medizinprodukte
|
|
US8137993B2
(en)
*
|
2004-03-25 |
2012-03-20 |
Veroscience Llc |
Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
|
|
US20050215558A1
(en)
*
|
2004-03-25 |
2005-09-29 |
Cincotta Anthony H |
Methods of identifying responders to dopamine agonist therapy
|
|
US8137994B2
(en)
*
|
2004-03-25 |
2012-03-20 |
Veroscience Llc |
Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
|
|
JP2007531537A
(ja)
*
|
2004-04-06 |
2007-11-08 |
セダーズ−シナイ メディカル センター |
アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
|
|
EP1602931A1
(de)
*
|
2004-06-03 |
2005-12-07 |
Universiteit Leiden |
SR-A Antagonisten
|
|
KR20070043711A
(ko)
*
|
2004-06-09 |
2007-04-25 |
아바니르 파마슈티컬스 |
고콜레스테롤혈증과 관련 질환의 치료를 위한 소분자
|
|
KR20070029198A
(ko)
*
|
2004-06-09 |
2007-03-13 |
아바니르 파마슈티컬스 |
고콜레스테롤혈증의 치료를 위한 역 콜레스테롤 수송의매개제
|
|
CN1968928A
(zh)
*
|
2004-06-09 |
2007-05-23 |
阿文尼尔药品公司 |
用于治疗高脂血症及相关疾病的杂环衍生物
|
|
EP1800126B1
(de)
*
|
2004-09-08 |
2014-12-17 |
The United States of America as represented by the Secretary of Health and Human Services, NIH |
Zusammensetzungen und verfahren für den nachweis von hiv-1/hiv-2-infektionen
|
|
CA2580501A1
(en)
*
|
2004-09-16 |
2006-03-30 |
The Regents Of The University Of California |
G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
|
|
AU2005295640B2
(en)
|
2004-10-15 |
2011-07-28 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Multi-domain amphipathic helical peptides and methods of their use
|
|
KR20070089996A
(ko)
|
2004-12-06 |
2007-09-04 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
세동맥의 구조 및 기능의 개선 방법
|
|
US7759315B2
(en)
|
2005-03-09 |
2010-07-20 |
Csl Behring Ag |
Treatment of inflammatory conditions of the intestine
|
|
US8206750B2
(en)
|
2005-03-24 |
2012-06-26 |
Cerenis Therapeutics Holding S.A. |
Charged lipoprotein complexes and their uses
|
|
MX2007013430A
(es)
*
|
2005-04-29 |
2008-03-19 |
Univ California |
Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
|
|
US20080293639A1
(en)
*
|
2005-04-29 |
2008-11-27 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
US20060275356A1
(en)
*
|
2005-05-25 |
2006-12-07 |
Burgess James W |
Pharmaceutical compositions for treating or preventing coronary artery disease
|
|
GR1005428B
(el)
*
|
2005-05-27 |
2007-02-01 |
Χαραλαμπος Αλεξοπουλος |
Συνθετικα λιποπεπτιδια με αντιαθηρογονο δραση, που εμποδιζουν την οξειδωση της λιποπρωτεϊνης χαμηλης πυκνοτητας (ldl) και αναστελλουν την απενεργοποιηση του ενζυμου της paf ακετυλοϋδρολασης (paf-ah)
|
|
KR101577554B1
(ko)
|
2005-08-22 |
2015-12-14 |
멜리어 파마슈티칼스 아이, 인코포레이티드 |
Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한 방법 및 제제
|
|
GB0602598D0
(en)
*
|
2006-02-09 |
2006-03-22 |
Cheesmond David |
Quick change front F2 sidecar
|
|
US20070254832A1
(en)
*
|
2006-02-17 |
2007-11-01 |
Pressler Milton L |
Methods for the treatment of macular degeneration and related eye conditions
|
|
TW200744627A
(en)
*
|
2006-02-21 |
2007-12-16 |
Pfizer Prod Inc |
Methods for the treatment of macular degeneration and related eye conditions
|
|
WO2007137400A1
(en)
*
|
2006-06-01 |
2007-12-06 |
Institut De Cardiologie De Montreal |
Method and compound for the treatment of valvular stenosis
|
|
US20080206142A1
(en)
*
|
2006-06-16 |
2008-08-28 |
Lipid Sciences, Inc. |
Novel Peptides That Promote Lipid Efflux
|
|
US20080199398A1
(en)
*
|
2006-06-16 |
2008-08-21 |
Brewer H Bryan |
Novel Peptides That Promote Lipid Efflux
|
|
US20080227686A1
(en)
*
|
2006-06-16 |
2008-09-18 |
Lipid Sciences, Inc. |
Novel Peptides that Promote Lipid Efflux
|
|
AU2007284801A1
(en)
*
|
2006-08-08 |
2008-02-21 |
The Regents Of The University Of Californina |
Salicylanilides enhance oral delivery of therapeutic peptides
|
|
WO2008039843A2
(en)
*
|
2006-09-26 |
2008-04-03 |
Lipid Sciences, Inc. |
Novel peptides that promote lipid efflux
|
|
CA3021932C
(en)
*
|
2007-01-31 |
2020-12-15 |
Jds Therapeutics, Llc |
Use of chromium histidinate for treatment of cardiometabolic disorders
|
|
CN101686686A
(zh)
*
|
2007-02-20 |
2010-03-31 |
梅里奥尔医药I公司 |
鉴别Lyn激酶激活剂的方法
|
|
ATE555801T1
(de)
|
2007-03-01 |
2012-05-15 |
Csl Ltd |
Behandlung von endothelialer dysfunktion bei diabetes-patienten
|
|
ES2579229T3
(es)
|
2007-03-13 |
2016-08-08 |
Jds Therapeutics, Llc |
Procedimientos y composiciones para la liberación sostenida de cromo
|
|
WO2009002867A2
(en)
|
2007-06-26 |
2008-12-31 |
Nutrition 21, Inc. |
Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
|
|
JP2010534668A
(ja)
*
|
2007-07-23 |
2010-11-11 |
メリオール・ディスカヴァリー・インコーポレイテッド |
Ｉｒｓ−１及びａｋｔを活性化する方法
|
|
EP2184987A4
(de)
*
|
2007-07-31 |
2011-09-28 |
Burnham Inst Medical Research |
Bidentatverbindungen als kinasehemmer
|
|
US8431529B2
(en)
*
|
2007-07-31 |
2013-04-30 |
Sanford-Burnham Medical Research Institute |
Bi-dentate compounds as kinase inhibitors
|
|
AU2008296478B9
(en)
|
2007-08-28 |
2015-03-19 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
|
CA2697504A1
(en)
*
|
2007-08-29 |
2009-03-12 |
The Regents Of The University Of California |
Salicylanilide modified peptides for use as oral therapeutics
|
|
US9173890B2
(en)
*
|
2007-09-20 |
2015-11-03 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US7985727B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Apo A-I mimetic peptides and methods of treatment
|
|
US8044021B2
(en)
*
|
2007-09-20 |
2011-10-25 |
Abbott Cardiovascular Systems Inc. |
Sustained release of apo A-I mimetic peptides and methods of treatment
|
|
US8101565B2
(en)
*
|
2007-09-20 |
2012-01-24 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US7985728B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US8936787B2
(en)
*
|
2008-04-15 |
2015-01-20 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Peptides promoting lipid efflux
|
|
US8552184B2
(en)
*
|
2008-07-03 |
2013-10-08 |
Melior Pharmaceuticals I, Inc. |
Compounds and methods for treating disorders related to glucose metabolism
|
|
DK2355851T3
(en)
|
2008-11-10 |
2018-06-25 |
Arbutus Biopharma Corp |
Newly known lipids and compositions for release of therapeutic agents
|
|
WO2010083611A1
(en)
|
2009-01-23 |
2010-07-29 |
Institut De Cardiologie De Montreal |
Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex
|
|
US20120101148A1
(en)
|
2009-01-29 |
2012-04-26 |
Alnylam Pharmaceuticals, Inc. |
lipid formulation
|
|
EP2396017B1
(de)
|
2009-02-16 |
2015-07-01 |
Cerenis Therapeutics Holding SA |
Apolipoprotein-a-i mimetika
|
|
NZ594995A
(en)
|
2009-03-12 |
2013-06-28 |
Alnylam Pharmaceuticals Inc |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
|
|
CA2760776C
(en)
|
2009-05-05 |
2019-07-09 |
Alnylam Pharmaceuticals, Inc. |
Lipid compositions for the delivery of therapeutic agents
|
|
WO2010135663A2
(en)
|
2009-05-21 |
2010-11-25 |
The United States Of America , As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for the detection of hiv-1/hiv-2 infection
|
|
US9352025B2
(en)
|
2009-06-05 |
2016-05-31 |
Veroscience Llc |
Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
|
|
CA2764609C
(en)
|
2009-06-10 |
2018-10-02 |
Alnylam Pharmaceuticals, Inc. |
Improved cationic lipid of formula i
|
|
AP2015008874A0
(en)
|
2009-08-14 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
|
CN102753576A
(zh)
*
|
2009-09-30 |
2012-10-24 |
首尔大学教产学协力团 |
载脂蛋白a-1模拟肽以及包含其的用于治疗高血脂及高血脂相关疾病的治疗剂
|
|
US12419839B2
(en)
|
2009-10-09 |
2025-09-23 |
Signablok, Inc. |
Methods and compositions for targeted delivery of protein fragments
|
|
US10894098B2
(en)
|
2012-04-09 |
2021-01-19 |
Signablok, Inc. |
Methods and compositions for targeted imaging
|
|
US10525152B2
(en)
|
2009-10-09 |
2020-01-07 |
Signablok, Inc. |
Methods and compositions for targeted imaging
|
|
CA2783372C
(en)
|
2009-12-07 |
2019-07-16 |
Muthiah Manoharan |
Compositions for nucleic acid delivery
|
|
AU2010330814B2
(en)
|
2009-12-18 |
2017-01-12 |
Acuitas Therapeutics Inc. |
Methods and compositions for delivery of nucleic acids
|
|
EP2517013A4
(de)
*
|
2009-12-23 |
2013-07-17 |
Artery Therapeutics Inc |
Diagnose und behandlung von erkrankungen im zusammenhang mit defizientem reversem cholesterintransport
|
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
US20130137628A1
(en)
|
2010-05-11 |
2013-05-30 |
Esperion Therapeutics, Inc. |
Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
|
|
WO2011150300A1
(en)
|
2010-05-28 |
2011-12-01 |
Melior Pharmaceuticals I, Inc. |
Prevention of pancreatic beta cell degeneration
|
|
CA2800401C
(en)
|
2010-06-03 |
2020-09-15 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
US20130323269A1
(en)
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
|
CN110123830A
(zh)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
|
EP2658993B1
(de)
|
2010-12-31 |
2014-10-01 |
Alphacore Pharma LLC |
Nachweis von lcat-aktivität
|
|
JP5902197B2
(ja)
|
2011-01-11 |
2016-04-13 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
Ｐｅｇ化脂質および薬剤送達のためのそれらの使用
|
|
HRP20190138T1
(hr)
|
2011-02-07 |
2019-03-22 |
Cerenis Therapeutics Holding Sa |
Lipoproteinski kompleksi i njihova proizvodnja i uporaba
|
|
AU2012223282B2
(en)
|
2011-03-01 |
2017-02-02 |
Nutrition 21, Llc |
Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
|
|
AU2012315965A1
(en)
|
2011-09-27 |
2014-04-03 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted PEGylated lipids
|
|
JP6108631B2
(ja)
*
|
2011-11-30 |
2017-04-05 |
デウン ファーマシューティカル カンパニー リミテッド |
高脂血症を予防または治療するための医薬組成物
|
|
CN107007608B
(zh)
|
2011-12-12 |
2021-04-23 |
梅里奥尔医药I公司 |
I型和ii型糖尿病的治疗
|
|
US10017551B2
(en)
|
2013-03-15 |
2018-07-10 |
The Regents Of The University Of California |
Peptides having reduced toxicity that stimulate cholesterol efflux
|
|
EP2853259A1
(de)
|
2013-09-30 |
2015-04-01 |
Université Pierre et Marie Curie (Paris 6) |
Rekonstituierte hochdichte Lipoproteinzusammensetzung und Verwendungen davon
|
|
KR20170003611A
(ko)
|
2014-05-02 |
2017-01-09 |
세레니스 쎄라퓨틱스 홀딩 에스에이 |
Ｈｄｌ 요법 마커
|
|
WO2016011049A2
(en)
|
2014-07-14 |
2016-01-21 |
Schwendeman Anna |
Compositions and methods for disease treatment using nanoparticle delivered compounds
|
|
AU2015298263B2
(en)
|
2014-07-31 |
2020-05-14 |
Anji Pharmaceuticals, Inc. |
ApoE mimetic peptides and higher potency to clear plasma cholesterol
|
|
WO2016149191A1
(en)
|
2015-03-13 |
2016-09-22 |
Esperion Therapeutics, Inc. |
Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
|
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
|
WO2016154542A2
(en)
*
|
2015-03-25 |
2016-09-29 |
The Regents Of The University Of Michigan |
Compositions and methods for treating cardiovascular related disorders
|
|
EP4537906A3
(de)
*
|
2015-03-25 |
2025-08-20 |
The Regents of the University of Michigan |
Zusammensetzungen und verfahren zur abgabe von biomakromolekülwirkstoffen
|
|
DK3319980T3
(da)
|
2015-07-10 |
2021-11-22 |
Peptinovo Biopharma Inc |
Formuleringer til forbedring af virkningen af hydrofobe lægemidler
|
|
AU2017217466A1
(en)
|
2016-02-11 |
2018-08-23 |
Nutrition 21, Llc |
Chromium containing compositions for improving health and fitness
|
|
EP3471778A4
(de)
|
2016-06-20 |
2020-02-19 |
The Regents of The University of Michigan |
Zusammensetzungen und verfahren zur abgabe von biomakromolekülwirkstoffen
|
|
BR112019001459A2
(pt)
|
2016-07-27 |
2019-05-07 |
Hartis-Pharma Sa |
combinação, composição farmacêutica, e, método de prevenção e/ou de tratamento de uma doença ou de um distúrbio.
|
|
FR3061715B1
(fr)
|
2017-01-12 |
2021-07-30 |
Institut National Univ Jean Francois Champollion |
Peptide immunomodulateur
|
|
MX387305B
(es)
|
2017-04-10 |
2025-03-18 |
Melior Pharmaceuticals I Inc |
Tratamiento de adipocitos
|
|
ES2984285T3
(es)
|
2017-08-10 |
2024-10-29 |
Abionyx Pharma Sa |
Cargómeros
|
|
WO2019084681A1
(en)
|
2017-10-30 |
2019-05-09 |
Montreal Heart Institute |
Methods of treating elevated plasma cholesterol
|
|
EP3714039B1
(de)
|
2017-11-22 |
2025-03-12 |
HDL Therapeutics, Inc. |
Verfahren zum primen von fluidkreisläufen eines plasmabearbeitungssystems
|
|
AU2018396009A1
(en)
|
2017-12-28 |
2020-07-16 |
Hdl Therapeutics, Inc. |
Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
|
|
CN110294791B
(zh)
*
|
2019-06-13 |
2023-02-21 |
倪京满 |
具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用
|
|
US12344578B2
(en)
|
2019-06-21 |
2025-07-01 |
Esperion Therapeutics, Inc. |
Salt forms of bempedoic acid and methods for using the same
|
|
US20240033322A1
(en)
|
2020-04-16 |
2024-02-01 |
Abionyx Pharma Sa |
Methods for treating acute conditions using lipid binding protein-based complexes
|
|
EP4221686A2
(de)
|
2020-10-01 |
2023-08-09 |
Abionyx Pharma SA |
Zusammensetzungen mit lipidbindenden komplexen auf proteinbasis zur verwendung zur behandlung von augenerkrankungen
|
|
WO2022219413A1
(en)
|
2021-04-15 |
2022-10-20 |
Abionyx Pharma Sa |
Use of lipid binding protein-based complexes in organ preservation solutions
|
|
JP2025511845A
(ja)
|
2022-04-06 |
2025-04-16 |
アビオニクス ファーマ エスエー |
脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
|
|
AU2023251245A1
(en)
|
2022-04-06 |
2024-11-14 |
Abionyx Pharma Sa |
Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
|
|
IL317448A
(en)
|
2022-06-10 |
2025-02-01 |
Abionyx Pharma Sa |
Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins
|
|
JP2025519606A
(ja)
|
2022-06-10 |
2025-06-26 |
アビオニクス ファーマ エスエー |
脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
|
|
JP2026504047A
(ja)
|
2023-01-13 |
2026-02-03 |
アビオニクス ファーマ エスエー |
脂質結合タンパク質分子療法
|
|
WO2025093929A1
(en)
|
2023-10-31 |
2025-05-08 |
Abionyx Pharma Sa |
Lipid binding protein molecule therapy
|